Bernhard R. M. Ehmer
Chairman at BIOTEST AG
Net worth: 87 025 $ as of 30/04/2024
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Uta Kemmerich-Keil | F | 58 | 23 years | |
| Harry Welten | M | 59 |
Affimed GmbH
 Affimed GmbH Miscellaneous Commercial ServicesCommercial Services Part of Affimed NV, Affimed GmbH is a clinical leader in innate immuno-oncology. The private company, based in Heidelberg, Germany, develops proprietary cancer-targeting bispecific antibodies that activate the innate immune system to kill tumor cells. Affimed leads clinical development of innate cell engagers for solid/hematologic tumors as monotherapy, in combination with NK cells or with checkpoint inhibitors. Adolf Hoess has been the CEO of the German company since 2010. | 4 years |
| Adolf Hoess | M | 62 |
Affimed GmbH
Affimed GmbH Miscellaneous Commercial ServicesCommercial Services Part of Affimed NV, Affimed GmbH is a clinical leader in innate immuno-oncology. The private company, based in Heidelberg, Germany, develops proprietary cancer-targeting bispecific antibodies that activate the innate immune system to kill tumor cells. Affimed leads clinical development of innate cell engagers for solid/hematologic tumors as monotherapy, in combination with NK cells or with checkpoint inhibitors. Adolf Hoess has been the CEO of the German company since 2010. | 14 years |
| Kai Beckmann | M | 58 | 35 years | |
| Ulrich Grau | M | 75 |
Affimed GmbH
Affimed GmbH Miscellaneous Commercial ServicesCommercial Services Part of Affimed NV, Affimed GmbH is a clinical leader in innate immuno-oncology. The private company, based in Heidelberg, Germany, develops proprietary cancer-targeting bispecific antibodies that activate the innate immune system to kill tumor cells. Affimed leads clinical development of innate cell engagers for solid/hematologic tumors as monotherapy, in combination with NK cells or with checkpoint inhibitors. Adolf Hoess has been the CEO of the German company since 2010. | 9 years |
| Ferdinand Verdonck | M | 81 |
Affimed GmbH
Affimed GmbH Miscellaneous Commercial ServicesCommercial Services Part of Affimed NV, Affimed GmbH is a clinical leader in innate immuno-oncology. The private company, based in Heidelberg, Germany, develops proprietary cancer-targeting bispecific antibodies that activate the innate immune system to kill tumor cells. Affimed leads clinical development of innate cell engagers for solid/hematologic tumors as monotherapy, in combination with NK cells or with checkpoint inhibitors. Adolf Hoess has been the CEO of the German company since 2010. | 10 years |
| Edwin Moses | M | 69 | - | |
| Thomas O. Hecht | M | 73 |
Affimed GmbH
Affimed GmbH Miscellaneous Commercial ServicesCommercial Services Part of Affimed NV, Affimed GmbH is a clinical leader in innate immuno-oncology. The private company, based in Heidelberg, Germany, develops proprietary cancer-targeting bispecific antibodies that activate the innate immune system to kill tumor cells. Affimed leads clinical development of innate cell engagers for solid/hematologic tumors as monotherapy, in combination with NK cells or with checkpoint inhibitors. Adolf Hoess has been the CEO of the German company since 2010. | 17 years |
| Peter Janssen | M | 58 | 2 years | |
| Iraj Ali | M | 48 | 6 years | |
| Dietmar Oeter | M | 57 | 29 years | |
| Karl Peggs | M | 57 | 4 years | |
| Carsten Boess | M | 57 | 4 years | |
| Daniel Hood | M | - | - | |
| Michael Giordano | M | 66 | 6 years | |
| Sergio Quezada | M | 49 | 4 years | |
| Gabriele Eismann | M | 62 | 33 years | |
| Mathieu Simon | M | 68 |
Affimed GmbH
Affimed GmbH Miscellaneous Commercial ServicesCommercial Services Part of Affimed NV, Affimed GmbH is a clinical leader in innate immuno-oncology. The private company, based in Heidelberg, Germany, develops proprietary cancer-targeting bispecific antibodies that activate the innate immune system to kill tumor cells. Affimed leads clinical development of innate cell engagers for solid/hematologic tumors as monotherapy, in combination with NK cells or with checkpoint inhibitors. Adolf Hoess has been the CEO of the German company since 2010. | 6 years |
| Jörg Schüttrumpf | M | 50 | 12 years | |
| Annalisa Jenkins | M | 58 |
Affimed GmbH
Affimed GmbH Miscellaneous Commercial ServicesCommercial Services Part of Affimed NV, Affimed GmbH is a clinical leader in innate immuno-oncology. The private company, based in Heidelberg, Germany, develops proprietary cancer-targeting bispecific antibodies that activate the innate immune system to kill tumor cells. Affimed leads clinical development of innate cell engagers for solid/hematologic tumors as monotherapy, in combination with NK cells or with checkpoint inhibitors. Adolf Hoess has been the CEO of the German company since 2010. | 4 years |
| Andreas Harstrick | M | 63 | 4 years | |
| Mary Beth Sandin | F | - | - | |
| Constanze Ulmer-Eilfort | M | 62 | 1 years | |
| Wolfgang Fischer | M | 60 |
Affimed GmbH
Affimed GmbH Miscellaneous Commercial ServicesCommercial Services Part of Affimed NV, Affimed GmbH is a clinical leader in innate immuno-oncology. The private company, based in Heidelberg, Germany, develops proprietary cancer-targeting bispecific antibodies that activate the innate immune system to kill tumor cells. Affimed leads clinical development of innate cell engagers for solid/hematologic tumors as monotherapy, in combination with NK cells or with checkpoint inhibitors. Adolf Hoess has been the CEO of the German company since 2010. | 7 years |
| Tariq Ahmed | M | - | 4 years | |
| Denise Mueller | F | 55 | 8 years | |
| Shree Patel | M | - | - | |
| Edward Samuel | M | - | 2 years | |
| Dirk Schuck | M | - | 2 years | |
| James Taylor | M | - | 2 years | |
| Robert Coutts | M | 40 | 4 years | |
| Drew Pantello | M | - | 6 years | |
| Christian Polus | M | - | - | |
| Dirk Neumüller | M | - | 23 years | |
| Martin Möller | M | - | - | |
| Alexander Fudukidis | M | - | 4 years | |
| Oliver Hein | M | - | 7 years | |
| Stephan Fleck | M | - | 22 years | |
| Enrico D'Aiuto | M | - | 9 years | |
| Josefine Buth | M | - | 23 years | |
| Susanne Hering | F | - | 9 years | |
| Julie O'Neill | F | 58 | 3 years | |
| Christina Erb | M | - | 12 years | |
| Jürgen Heilmann | M | 62 | 42 years | |
| David Bell | M | 70 | 2 years | |
| Monika Buttkereit | M | - | 15 years | |
| Raimon Grifols Roura | M | 61 | 1 years | |
| Tomás Dagá Gelabert | M | 68 | 2 years | |
| Ruediger Weseloh | M | - | 18 years | |
| Ainhoa Mendizabal Zubiaga | F | 52 | 1 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Michael Kemmer | M | 67 |
Ludwig-Maximilians-Universität München
| 5 years |
| Alexander Dibelius | M | 65 |
Ludwig-Maximilians-Universität München
| 9 years |
| Atef Kamal Sadeq Alawneh | M | 75 |
Ludwig-Maximilians-Universität München
| 6 years |
| Karl-Ludwig Kley | M | 72 |
Ludwig-Maximilians-Universität München
| 14 years |
| Rainer Lichtenberger | M | 65 | 14 years | |
| Matthew Emmens | M | 72 | 4 years | |
| Michael Ramroth | M | 63 | 21 years | |
| Thomas Mayrhofer | M | 64 |
Ludwig-Maximilians-Universität München
| 7 years |
| Dieter Kempf | M | 70 |
Ludwig-Maximilians-Universität München
| 5 years |
| Paul Friedrich Lerbinger | M | 68 |
Ludwig-Maximilians-Universität München
| 7 years |
| Friederike Rotsch | M | 51 | 18 years | |
| Alfred Gossner | M | - |
Ludwig-Maximilians-Universität München
| 9 years |
| Michael Feldhahn | M | 70 |
Ludwig-Maximilians-Universität München
| 6 years |
| Georg Floß | M | 63 | 14 years | |
| Detlef Eberle | M | - |
Ludwig-Maximilians-Universität München
| - |
| Veit Ulshöfer | M | 61 | 23 years | |
| Rick Ryan | M | - | 11 years | |
| François Diederich | M | 72 |
Ruprecht-Karls-Universität Heidelberg
| 6 years |
| Peter Kossubek | M | 70 |
Ludwig-Maximilians-Universität München
| 8 years |
| Christoph Walbrecht | M | - |
Ludwig-Maximilians-Universität München
| 6 years |
| Berndt A. E. Modig | M | 65 | 6 years | |
| Christian Schetter | M | 60 |
Neovii Biotech GmbH
 Neovii Biotech GmbH BiotechnologyHealth Technology Neovii Biotech GmbH develops and markets biopharmaceutical products in the field of transplantation. The company was founded in 2003 and is headquartered in Gräfelfing, Germany. | 6 years |
| Gregory W. Gin | M | - | - | |
| Renate Köcher | M | 71 |
Ludwig-Maximilians-Universität München
| 8 years |
| Wolfgang Schäfer | M | 65 |
Ludwig-Maximilians-Universität München
| 5 years |
| Patrick Baeuerle | M | 66 |
Ludwig-Maximilians-Universität München
| 9 years |
| Mads Laustsen | M | 67 |
Symphogen A/S
 Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | 5 years |
| Florian Fischer | M | 56 | 15 years | |
| Rudolf Staudigl | M | 69 |
Ludwig-Maximilians-Universität München
| 4 years |
| Thomas Tochtermann | M | 63 |
Ludwig-Maximilians-Universität München
| 4 years |
| Mustafa Ahmad Abdulhafiz Salhab | M | 74 |
Ruprecht-Karls-Universität Heidelberg
| 4 years |
| Erwin Kern | M | 63 |
Ludwig-Maximilians-Universität München
| 4 years |
| Stefan Oschmann | M | 66 |
Ludwig-Maximilians-Universität München
| 3 years |
| Michael Christian Knorz | M | 65 |
Ruprecht-Karls-Universität Heidelberg
| 4 years |
| Eva-Maria Haiduk | F | 62 |
Ludwig-Maximilians-Universität München
| 7 years |
| Christoph Wahlbrecht | M | - |
Ludwig-Maximilians-Universität München
| 1 years |
| Cengiz Selman | M | - |
Ludwig-Maximilians-Universität München
| 3 years |
| Michael Albrecht | M | 74 |
Ludwig-Maximilians-Universität München
| 3 years |
| Thomas Posovatz | M | 64 |
Ludwig-Maximilians-Universität München
| 7 years |
| Luis Miguel Cardozo Goytizolo | M | 73 |
Ruprecht-Karls-Universität Heidelberg
| 3 years |
| Hans Heinrich Driftmann | M | 76 |
Ludwig-Maximilians-Universität München
| 5 years |
| Claus S. Hass | M | - |
Ludwig-Maximilians-Universität München
| 3 years |
| Wilhelm Seiler | M | 74 |
Ludwig-Maximilians-Universität München
| 3 years |
| Jost Massenberg | M | 67 |
Ludwig-Maximilians-Universität München
| 4 years |
| Sven Quandt | M | 68 |
Ludwig-Maximilians-Universität München
| 4 years |
| Erik Max Michael Obermayer | M | 76 |
Ludwig-Maximilians-Universität München
| 3 years |
| Martin Madaus | M | 64 |
Ludwig-Maximilians-Universität München
| 3 years |
| Crocifissa Attardo | F | 62 | 23 years | |
| Rolf Burkhardt | M | - |
Ludwig-Maximilians-Universität München
| 3 years |
| Franz-Josef Busse | M | 76 |
Ludwig-Maximilians-Universität München
| 7 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Germany | 85 | 85.00% |
| United Kingdom | 13 | 13.00% |
| Denmark | 1 | 1.00% |
| United States | 1 | 1.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Bernhard R. M. Ehmer
- Personal Network